Vaginal active agent delivery procedures and formulations thereof

• US 20030007994A1
• Filed: 06/03/2002
• Published: 01/09/2003
• Est. Priority Date: 06/18/1998
• Status: Abandoned Application

• Current Assignee: Interag
• Original Assignee: Interag
• Inventors: Rathbone, Michael John, Burggraaf, Shane, Bunt, Craig Robert
• Application Number:
  US10/159,289
• Publication Number:
  US 20030007994A1
• Time in Patent Office: Days
• US Class Current: 424/433
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 47/40 Cyclodextrins; Derivatives thereof
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 5/30 Oestrogens

Abstract

Intra-vaginal delivery procedures including compositions and units therefor whereby an effective releasable amount of oestradiol 17β is released to achieve an efficacious effect insofar as oestrus expression is concerned. Preferably a cyclodextrin is utilized to enhance absorption.

Claims

1. An intra-vaginal composition for intra vaginal administration into a mammal, said composition being or having, as a solids admixture, an active principle in admixture with γ

-cyclodextrin and/or hydroxypropyl β

-cyclodextrin.

2. A composition of claim 1 when in the form of a tablet or as part of a capsule.

3. A composition of claim 1 or 2 wherein said active principle is selected from the group consisting of (i) oestradiol benzoate, (ii) oestradiol 17β

, (iii) prodrugs of (i) and, (iv) prodrugs of (ii).

4. A composition or claim 1, 2 or 3 wherein said active principle is oestradiol 17β

.

5. A composition as claimed in any one of the preceding claims wherein said active principle is to achieve, in a target mammal, an efficacious effect insofar as oestrus expression is concerned.

6. A composition as claimed in any one of the preceding claims wherein said active principle is to achieve, in a target mammal, an efficacious effect insofar as oestrus synchronisation is concerned.

7. A composition as claimed in any one of the preceding claims as a dosage unit for a target mammal where the active principle is oestradiol 17β

in an amount of between 0.72 and 7.2 mg.

8. A composition as claimed in any one of the preceding claims wherein the active principle is oestradiol 17β

and there is between 0.5 to 1.5 moles of γ

-cyclodextrin and/or hydroxypropyl β

-cyclodextrin per mole of oestradiol 17β

.

9. The use of a composition as claimed in any one of claims 4, 7 and 8 wherein after an insertion of said composition as an intra-vaginal dosage unit in a target mammal, the plasma oestradiol concentration in the mammal 2 hours following the intra-vaginal administration is greater than 5 pg/ml and 24 hours following the intra-vaginal administration is less than 5 pg/ml.

10. The use of γ

-cyclodextrin and/or hydroxypropyl β

-cyclodextrin as absorption enhances in the preparation of a pharmaceutical composition for the intra-vaginal administration of at least one active principle, said composition being a composition as claimed in any one of claims 1 to 9.

15. A procedure of any one of claims 11 to 14 wherein the oestradiol co-treatment is also a use as claimed in claim 9 or 10.

11. In a mammalian herd oestrus synchrony procedure which involves the insertion into and the subsequent withdrawal from each mammal of the herd of an intra vaginal device adapted to deliver progesterone, the use of an oestradiol co-treatment which involves a timely intra vaginal insertion into each such mammal of an intra vaginal dosage form having an active principal selected from the group consisting of (i) oestradiol benzoate, (ii) oestradiol 17β

, (iii) prodrugs of (i) and, (iv) prodrugs of (ii) in admixture with a cyclodextrin selected from the group consisting of γ

-cyclodextrin and hydroxypropyl β

-cyclodextrin.

13. A procedure of claim 11 or 12 wherein the active principal is oestradiol 17β

.

14. A procedure of claim 13 wherein there are between 0.5 to 1.5 moles of γ

-cyclodextrin and/or hydroxypropyl β

-cyclodextrin per mole of oestradiol 17β

.

16. A procedure of any one of claims 11 to 15 wherein said oestradiol co-treatment intra vaginal dosage form is a tablet or capsule.

17. A procedure as claimed in claim 16 wherein each such tablet or capsule does not require active removal prior to, during or subsequent to the removal of said intra vaginal device adapted to deliver progesterone.

19. A tablet or capsule of claim 18 capable in a target species recipient mammal of providing a plasma oestradiol concentration in the mammal two hours following intra vaginal administration of the table or capsule that is greater than 5 pg/ml and which 24 hours following the intra vaginal administration of the tablet or capsule will be less than 5 pg/ml.

20. A tablet or capsule of claim 18 or 19 having from 1.2 to 7.2 mg of oestradiol 17β

and from 6 to 150 mg of cyclodextrin(s).

12. In a mammalian oestrus expression procedure which involves the insertion into and the subsequent withdrawal from each mammal of the herd of an intra vaginal device adapted to deliver progesterone, the use of an oestradiol co-treatment which involves a timely intra vaginal insertion into each such mammal of an intra vaginal dosage form having an active principal selected from the group consisting of (i) oestradiol benzoate, (ii) oestradiol 17β

, (iii) pro drugs of (i) and, (iv) prodrugs of (ii) in admixture with a cyclodextrin selected from the group consisting of γ

-cyclodextrin and hydroxypropyl β

-cyclodextrin.

18. An intra vaginal tablet or capsule formed of or having from 0.72 to 7.2 mg of oestradiol 17β

in admixture with a cyclodextrin selected from one or both of γ

-cyclodextrin and/or hydroxypropyl β

-cyclodextrin, the mole ratio of the cyclodextrin(s) to oestradiol ranging from 0.5;

1 to 1.5;

1.

21. An intra vaginal table or capsule formed or having an analogue of oestradiol 17β

in an amount equivalent to 0.72 to 7.2 mg of oestradiol 17β and

from 6 to 150 mg cyclodextrin(s).

22. A tablet or capsule of claim 21 wherein said analogue is present in an amount equivalent to 1.2 to 7.2 mg of oestradiol 17β

.

23. A tablet or capsule of claim 22 wherein said analogue is oestradiol benzoate present in an amount from 10 to 30 mg, being an analogue equivalent amount to 1.2 to 7.2 mg of oestradiol 17β

.